MetaVia DA-1726 late-breaking abstract accepted for EASL 2026 poster; Phase 1 data expected Q4

MetaVia Inc.

Abstract LB26-5204 on DA-1726 (GLP-1/glucagon dual agonist) accepted for poster at EASL Congress 2026 in Barcelona (May 27-30).
Poster title: Safety, Tolerability, PK, PD of DA-1726 in higher-dose Phase 1 cohort with exploratory liver assessment.
Phase 1 Part 3 titration study ongoing; optimizing higher dose levels and tolerability; data expected Q4 2026.
Presenting author: Chris Fang, CMO; poster available on MetaVia website after presentation.

item 7.01item 9.01

Source: SEC EDGAR

accession 0001104659-26-058332

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.